IngredientsBarrenwort belongs to the genus Epimedium (family Berberidaceae), a genus of about 52 species. It is also known as Rowdy Lamb Herb, Xianlinpi, Barrenwort, Bishop's Hat, Fairy Wings, Horny Goat Weed, and Yangheye or Yin Yang Huo (Chinese: 淫羊藿). These are herbaceous flowering plants that have been widely used as a tonic, aphrodisiac, and antirheumatic in China, Japan, and Korea for more than 2,000 years.
Although the term "Barrenwort" can, in a broad botanical sense, refer to any species within Epimedium, the species most extensively documented in pharmacological and clinical research are:
Epimedium is native to higher and drier areas of China and Tibet. It is an ivy-like shrub that has been described in Shennong's herbal classic and is increasingly used to prevent and treat various diseases, including cardiovascular, skeletal, neuroendocrine, and immune disorders.
In commerce and research, the official drug material is designated Herba Epimedii (also rendered as Epimedii Folium), which refers specifically to the aerial parts — predominantly the leaves — of the plant. Extracts of the aerial parts of this genus are used in a famous botanical supplement widely used as a tonic, aphrodisiac, and antirheumatic in China, Japan, and Korea for more than 2,000 years.
More than 15 species in the genus Epimedium have a long history of use in traditional Chinese medicine (TCM) and are believed to "nourish the kidney and reinforce the Yang." The classic Chinese medicine literature Shen Nong's Materia Medica recorded more than 400 years ago that Herba Epimedii has the effects of "tonifying kidney yang," "strengthening muscles and bones," and "dispelling rheumatism."
Epimedium brevicornum Maxim., a Traditional Chinese Medicine, has been used for the treatment of impotence, sinew and bone disorders, "painful impediment caused by wind-dampness," numbness, spasms, hypertension, coronary heart disease, menopausal syndrome, bronchitis, and neurasthenia for many years in China.
The common name "Horny Goat Weed" is attributed to a legend that a goat herder noticed increased sexual activity in his flock after they consumed the plant. This folklore origin, recorded in early Chinese texts, was the basis for naming the herb's yang-invigorating property.
Epimedii Folium (EF) is a famous herbal medicine that contains several medically active constituents, including flavonoids and phytosteroids, which are commonly used in China, Japan, and Korea.
In classical TCM, the herb was most commonly prepared as a decoction (a water-extracted tea). Epimedium is an herb used in traditional Chinese medicine to treat fatigue, arthritic pain, nerve pain, and sexual dysfunction. Modern Chinese herbal medicine uses epimedium — usually in combination with other herbs — not just to treat impotence, but also for asthma, bronchitis, cervical dysplasia, congestive heart failure, leucorrhoea, leukopenia, and viral infections of the heart. Epimedium is also used to treat menopause in women, often combined with Morinda.
TCM theory conceptually classified the herb's effects under three principal categories: (1) invigorating kidney yang and enhancing sexual function; (2) strengthening sinews and bones; and (3) expelling "wind-cold-dampness" to relieve rheumatic and arthritic complaints. Herbal Epimedium species have been widely used in TCM for sexual enhancement, immunity improvement, and slow-aging treatment, with flavonoids and polysaccharides being the major active components.
More than 260 compounds have been isolated from Epimedium; among them, prenyl-flavonoids are the major constituents and also important chemotaxonomic markers. The prenyl (3-methylbut-2-enyl) modification attached to the flavonoid backbone is a hallmark chemical feature of the genus and is responsible for the genus's characteristic pharmacological profile. The principal flavonoid classes identified in Epimedium include icariin and its metabolic derivatives, epimedins, icariside series, baohuosides, and the aglycones icaritin and desmethylicaritin.
The primary active component of Epimedium is icariin (ICA), an isoprenylated flavonoid. Icariin is the most abundant constituent in Herba Epimedii. Chemically, icariin is classified as a prenylated flavonol glycoside. Its chemical structure is characterized by a unique arrangement of functional groups; it consists of 33 carbon atoms, 40 hydrogen atoms, and 15 oxygen atoms.
Upon oral ingestion, icariin itself has limited bioavailability in its intact form. Modern studies have shown that epimedium herb is rich in icariin, and 91.2% of icariin is converted to icariside II (ICA II) by hydrolytic enzymes in intestinal bacteria after oral administration. Icariin has a chemical structure of glycosides, which is one of the reasons for its low oral bioavailability. The metabolites icariside I, icariside II, icaritin, and desmethylicaritin are therefore considered pharmacologically relevant circulating forms after oral dosing.
Like sildenafil, icariin is a phosphodiesterase type-5 inhibitor. Icariin and its analogs are inhibitors of PDE5. PDE5 inhibitors, including sildenafil and icariin analogs, promote aromatase expression in human ovarian granulosa-like KGN cells by activating the cAMP/CREB pathway. PDE5 normally degrades cyclic guanosine monophosphate (cGMP); inhibition by icariin allows cGMP to accumulate, promoting smooth muscle relaxation and vasodilation in vascular and cavernous tissues.
Extract of Epimedium relaxes the corpus cavernosum smooth muscle through multi-targets in the nitric oxide (NO)/cyclic guanosine monophosphate/PDE5 pathway, and might bring into perspective the treatment strategy for patients with erectile dysfunction.
Mechanistically, ICA exerts dual-regulation effects by promoting osteogenesis while inhibiting osteoclastogenesis, coupled with multi-target actions involving autophagy regulation, anti-inflammatory effects, iron overload mitigation, and oxidative stress reduction. Studies across postmenopausal, glucocorticoid-induced, aging, and diabetic osteoporosis models consistently demonstrate ICA's ability to improve bone microarchitecture and BMD.
At the molecular level, ICA exerts central effects by synergistically activating osteogenic pathways (e.g., SPI1/SMAD5, Wnt/β-catenin) and inhibiting osteoclastogenesis (e.g., Cullin 3/Nrf2, RANKL-p38/ERK-NFAT).
After treatment with icariin, the activity of the osteoclast differentiation marker TRAP significantly decreased at a concentration of 10−8 M. Icariin also inhibited LPS-induced bone resorption and interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) expression. The gene expression of osteoprotegerin (OPG) was up-regulated, while receptor activator of NF-κB ligand (RANKL) was down-regulated.
ICA can relieve the inhibition of PDE5 on aromatase P450 and promote the catalytic synthesis of estrogen from C19 androgen. Animal experiments have shown that ICA can act as an estrogen analog to protect ovariectomized rats by increasing osteogenesis and angiogenesis. The underlying mechanism is that ICA can activate ERα and Akt by inducing IGF-1 production to promote bone formation.
In undifferentiated neuronal cell lines, icariin exhibited neuroprotective effects through LDH leakage attenuation, which reduced GSH depletion, prevented DNA oxidation damage, and inhibited caspase-3 and p53 activation; it also inhibited JNK/p38 MAPK pathways.
In a rat model of Alzheimer's disease, Aβ1–42 injection induced loss of learning and memory behaviour in the Morris water maze, which could be reversed with intragastric administration of ICA. Furthermore, ICA reversed decreases in PSD-95, BDNF, pTrkB, pAkt, and pCREB expressions and prevented deterioration of synaptic interface structure.
Modern pharmacology studies and clinical practice have demonstrated that Epimedium and its active compounds possess wide pharmacological actions, including immunological function modulation, anti-oxidation, anti-tumor, anti-aging, anti-atherosclerosis, and anti-depressant activities.
Epimedium showed anticancer effects, as well as anti-HIV activity, in preclinical studies. Epimedium derivatives also produced radiosensitizing effects and reversed multidrug resistance in tumor cells. It has been implicated in differentiation of stem cells into cardiomyocytes via cell cycle regulation, induction of apoptosis, modulation of reactive oxygen species generation, and the regulation of various signaling pathways.
ICA decreased Cyp2e1 enzyme activity in mice but induced Cyp3a enzyme activity in rats. ICA has also been shown to inhibit UDP-glucuronosyltransferases, particularly Ugt1 family enzymes, in vitro.
Overview: This is the area with the most substantial human clinical evidence for barrenwort / Epimedium extracts.
Landmark Randomized Controlled Trial (2007): A 24-month randomized, double-blind, placebo-controlled clinical trial evaluated the effect of Epimedium-derived phytoestrogen flavonoids (EPFs) on bone mineral density (BMD), bone turnover biochemical markers, serum estradiol, and endometrial thickness in postmenopausal women. One hundred healthy late postmenopausal women, with BMD T-scores at the lumbar spine between −2 and −2.5 SD, were randomized into EPF treatment group (n = 50; a daily dose of 60 mg icariin, 15 mg daidzein, and 3 mg genistein) or placebo control group (n = 50). All participants received 300 mg elemental calcium daily. BMD, bone turnover biochemical markers, serum estradiol, and endometrial thickness were measured at baseline and 12 and 24 months after intervention. Eighty-five participants completed the trial.
BMD was found with a decreased tendency in the placebo control group at 12 months (femoral neck: −1.4%; lumbar spine: −1.7%) and 24 months (femoral neck: −1.8%; lumbar spine: −2.4%), whereas EPF treatment maintained BMD at 12 months (femoral neck: 1.1%; lumbar spine: 1.0%) and 24 months (femoral neck: 1.6%; lumbar spine: 1.3%). The difference in lumbar spine between the two groups was significant at both 12 months (p = 0.044) and 24 months (p = 0.006), whereas the difference in the femoral neck was marginal at 12 months (p = 0.061) and significant at 24 months (p = 0.008).
Second Clinical Trial (2021): In a randomized controlled trial, administration of Epimedium prenylflavonoid extract (740 mg daily) for six weeks to 58 postmenopausal women (aged 57.9 ± 8.9 years) produced positive benefits on osteoporosis by increasing the bone anabolic marker BSAP (bone-specific alkaline phosphatase) due to the metabolite desmethylicaritin.
Evidence Strength: Bone health represents the most mature area of human evidence. Two placebo-controlled RCTs exist, both conducted in postmenopausal women. The 2007 trial is the more definitive, with a 24-month duration and a primary BMD endpoint. Limitations include: small sample sizes (50 per group), the use of a multi-flavonoid formulation (not isolated icariin alone), and co-supplementation with calcium, making it difficult to isolate the effect of icariin specifically. Evidence is promising but preliminary; large independent replication trials are needed before clinical recommendations can be made.
Preclinical Evidence: Icariin at low doses (1, 5, and 10 mg/kg) produced erectogenic and neurotrophic effects in rats with cavernous nerve injury, with increased intracavernous pressure/mean arterial pressure ratio. The NO/cGMP/PDE5 pathway is a well-documented mechanism in these animal models.
Human Clinical Evidence: A randomized, double-blind, placebo-controlled crossover study of herbal medicine including Epimedium was conducted for the treatment of erectile dysfunction (ED) in Thailand in 2013. Sixty-one adult patients with mild to moderate ED were randomized to receive herbal medicine with Epimedium or identical-looking placebo: patients were randomized to receive herbal medicine for two weeks, then switched to receive placebo for another two weeks, with a one-week washout period, and vice versa for the other group. The International Index of Erectile Function (IIEF) questionnaire was used to assess the effects of therapy. IIEF scores were collected at baseline and at the end of each treatment period.
A small pilot placebo-controlled study of icariin in patients with sexual dysfunction examined patients with an IIEF-5 symptom score. This clinical test was conducted for 56 patients suffering from sexual dysfunction who agreed to the study. The mean age of the patients was 36 ± 6.7 years. The patients were randomly classified into two groups, one for icariin and another for placebo. The test drug (icariin 50 mg/tablet, 2 tablets/dose, 3 times/day) and placebo were administered to patients for one month.
Evidence Strength: Human clinical evidence for erectile dysfunction is very limited in quantity and quality. The existing studies are small, often use multi-herb formulations rather than isolated icariin, and have short treatment durations. Preclinical (animal and cell-based) data on PDE5 inhibition and penile hemodynamics are comparatively robust, but do not translate directly to verified human efficacy. Overall evidence is preliminary and insufficient to draw clinical conclusions.
Preclinical Evidence: Recent animal experimental studies indicate that icariin, a major bioactive component of Epimedium, may effectively treat Alzheimer's disease, cerebral ischemia, depression, Parkinson's disease, and multiple sclerosis, as well as delay aging.
Icariin (ICA), a prenylated flavanol glycoside present in abundant quantities in Epimedium sagittatum, has shown promise in the treatment and prevention of Alzheimer's disease. Damage to synaptic plasticity induced by amyloid-beta-mediated neurotoxicity is considered a main pathological mechanism driving the learning and memory deficits present in patients with Alzheimer's disease.
Studies using wushanicaritin, another Epimedium constituent, found that wushanicaritin possessed superior intercellular antioxidant activity compared to icaritin; with an EC50 value of 3.87 μM, it showed a better neuroprotective effect than quercetin.
Human Evidence: A randomized, double-blind, placebo-controlled safety and pharmacokinetics study examined oral icariin at doses of 100 to 1,680 mg/day in 24 healthy adult participants over 5 days, with cognition and mood assessed. At all doses, either very low or undetectable blood levels of icariin were observed, demonstrating the low bioavailability of the oral formulation. No significant between-group differences were observed on side effect scales or on cognitive assessments.
Evidence Strength: Evidence for cognitive and neuroprotective effects is entirely preclinical (animal models, cell lines). No human clinical trials examining cognition as a primary endpoint have been reported. The pharmacokinetic finding of very low oral bioavailability of icariin itself raises questions about whether meaningful brain concentrations can be achieved with standard oral supplementation.
Epimedium showed immunomodulatory effects in preclinical studies. Research has shown that polysaccharide and flavonoid fractions of Epimedium can modulate immune cell function — including natural killer (NK) cell activity and cytokine production — in animal models. Evidence in humans is absent; all immunomodulatory data come from in vitro cell studies or animal experiments.
In terms of function, icariin plays a protective and anti-tumor role in various cardiovascular, skeletal, central nervous, immune, respiratory, and reproductive systems. Preclinical studies suggest anti-atherosclerotic and cardioprotective effects, including modulation of lipid metabolism and anti-inflammatory signaling in vascular tissue. No human cardiovascular endpoint trials have been reported.
The classic Chinese medicine literature recorded that Herba Epimedii has the effects of "tonifying kidney yang," "strengthening muscles and bones," and "dispelling rheumatism." Traditional Chinese medicine has a history of thousands of years in treating asthma. In recent years, many new research advances have been made on the specific mechanism of action of icariin in the treatment of asthma. Icariin has various biological attributes such as anti-inflammatory and antioxidative activities, and immune regulation. This body of work remains at the preclinical stage; no clinical trials in asthma populations have been published as of available evidence.
Herbal Epimedium species have been widely used in TCM for sexual enhancement, immunity improvement, and slow-aging treatment, with flavonoids and polysaccharides being the major active components. Mechanisms proposed in animal models include antioxidant activity, telomere-protective effects, and mitochondrial preservation. Evidence in humans is absent.
All evidence for anticancer activity of icariin and related compounds is at the preclinical (in vitro and animal model) stage only. Epimedium showed anticancer effects in preclinical studies. Epimedium derivatives also produced radiosensitizing effects and reversed multidrug resistance in tumor cells. No human oncology trials involving icariin as a primary intervention have been published.
The following dosages are reported directly from peer-reviewed clinical and pharmacological studies and are presented for informational reference only, as reported by source authors:
It is important to note that at all doses tested (100–1,680 mg/day), either very low or undetectable blood levels of icariin were observed in humans, demonstrating the low bioavailability of the oral formulation. Circulating metabolites (icariside II, desmethylicaritin) are the pharmacologically relevant species after oral dosing, but their clinical implications remain under investigation.
While preclinical studies are promising, clinical trials are necessary to validate these effects in humans and determine appropriate dosing, safety, and efficacy. Epimedii Folium (EF) is a well-known herbal medicine employed extensively as a tonic, aphrodisiac, and antirheumatic. In recent years, the possibility that EF and its preparations cause idiosyncratic drug-induced liver injury (IDILI) has been reported frequently, and clinical safety issues associated with EF have drawn increasing attention.
Icariside II (ICS II), the major active and metabolic constituent of EF, causes idiosyncratic liver injury by promoting NLRP3 inflammasome activation. Epimedii Folium has been shown to cause idiosyncratic liver injury, but the underlying mechanisms are poorly understood. Increasing evidence has indicated that most cases of IDILI are immune-mediated. Icariside II specifically causes idiosyncratic liver injury by promoting NLRP3 inflammasome activation.
Among tested substances, ethanol extracts exhibited stronger hepatotoxicity, with icariside I and sagittatoside A correlating with this toxic effect; the hepatotoxic mechanisms may be associated with damaged cell structure, increased oxidative stress, and induction of apoptosis.
The hepatotoxicity of Herba Epimedii, like other TCMs, is probably due to the combined effects of multiple components, and the possibility exists of specific hepatotoxicity related to idiosyncratic and hypersensitive responses to drugs.
One case report describes a 33-year-old man who developed severe muscle spasms with elevated creatine kinase (CK) and creatinine following the use of Epimedium as an over-the-counter supplement. Symptoms and laboratory abnormalities resolved with supportive care and discontinuation of the supplement. This was reported as the first published case linking Epimedium to such findings.
In vitro evidence indicates that icariin and its intestinal metabolites are potent inhibitors of several UGT isoforms. Icariin exhibited potent inhibition against UGT1A3. Icariside II was a potent inhibitor of UGT1A4, UGT1A7, UGT1A9, and UGT2B7; icaritin was a potent inhibitor of UGT1A7 and UGT1A9. Quantitative prediction of risks indicated that in vivo inhibition against intestinal UGT1A3, UGT1A4, and UGT1A7 would likely occur after oral administration of icariin products. UGT enzymes are responsible for the glucuronidation and elimination of many pharmaceutical drugs; their inhibition could alter the blood levels and toxicity of co-administered medications.
CYP3A4 is a major drug-metabolizing enzyme for corticosteroids (CS). Epimedium has been used for asthma and a variety of inflammatory conditions with or without CS. In vitro data suggest that epimedium constituents can suppress CYP3A4 activity; this finding implies potential for interactions with the large array of drugs metabolized by CYP3A4, which includes many statins, immunosuppressants, antifungals, certain antivirals, and benzodiazepines. These interactions have not been definitively characterized in humans.
Because icariin and its metabolites exhibit phytoestrogenic activity — acting as partial estrogen receptor agonists — the use of barrenwort preparations may be of theoretical concern in individuals with hormone-sensitive conditions. Epimedium is thought to alter levels of certain hormones and is marketed as a dietary supplement for libido. The 2007 RCT specifically measured endometrial thickness as a safety endpoint and found no significant changes, providing some reassurance for short- to medium-term use in postmenopausal women, but long-term hormonal safety data are lacking.
At all doses tested in the human pharmacokinetics study (100–1,680 mg/day), either very low or undetectable blood levels of icariin were observed, demonstrating the low bioavailability of the oral formulation. This variability, partly dependent on individual intestinal microbiome composition (which drives the conversion of icariin to bioactive metabolites), means that the pharmacological effect of any given oral dose is difficult to predict across individuals.
Health conditions that Barrenwort may help support.
Epimedium is traditionally used in TCM as a tonic for male sexual dysfunction and aging. Icariin has been shown to exhibit testosterone-mimetic properties in animal models, improve age-related testicular dysfunction, and restore Sertoli cell function. Studies show it may restore low testosterone and improve sexual vitality in aging males, though dedicated human RCTs for andropause endpoints are absent.
Icariin and Epimedium flavonoids activate the Nrf2 antioxidative signaling pathway, increase SOD activity, reduce lipid peroxidation markers (MDA), and scavenge reactive oxygen species in multiple organ models. Antioxidant effects are documented in brain, kidney, heart, and reproductive tissue. This is considered one of Barrenwort's primary pharmacological mechanisms.
Icariin has been studied for both osteoarthritis and rheumatoid arthritis in preclinical models, demonstrating cartilage-protective, anti-inflammatory, and chondrocyte-survival effects. The 2025 Frontiers in Pharmacology narrative review confirmed ICA's efficacy in bone and joint disease, including joint disorders. Traditional TCM uses include osteoarthritis and arthralgia.
Epimedium and its bioactive compounds including icariin have been reviewed for respiratory disease management, with anti-inflammatory, antioxidant, and immunomodulatory mechanisms documented as relevant to asthma. A 2025 ScienceDirect comprehensive narrative review specifically examined Epimedium's effects on respiratory diseases including asthma. Traditional use for bronchitis and asthma is documented across multiple historical and ethnopharmacological sources.
Icariin inhibits α-glucosidase enzyme activity—a mechanism directly relevant to postprandial blood glucose control—and has demonstrated glucose-lowering effects in multiple diabetic animal models. It also modulates glucose/lipid metabolism and insulin signaling pathways. Evidence is predominantly preclinical; human glycemic trials are not yet established.
Icariin, Barrenwort's primary flavonoid, has been tested in a 24-month randomized double-blind placebo-controlled trial in postmenopausal women, demonstrating beneficial effects on bone mineral density (BMD) with low side effects. Icariin promotes osteoblast differentiation and mineralization while inhibiting osteoclast-mediated bone resorption via estrogen receptor ERα and RANKL/RANK signaling. Multiple systematic reviews and meta-analyses confirm modest but consistent improvements in lumbar spine and femoral neck BMD.
Icariin and Epimedium extracts suppress key pro-inflammatory pathways including NF-κB, TLR4/MD-2, NLRP3 inflammasome, and TNF-α in multiple in vitro and in vivo models. Anti-inflammatory activity is documented across tissues including kidney, bone, joint, and heart. These mechanisms underpin Barrenwort's broad therapeutic applications.
Epimedium prenylflavonoids produce NO-dependent vasorelaxation of coronary arteries, upregulate eNOS in endothelial cells, and have demonstrated positive actions on vascular reactivity and endothelial function in human subjects. Epimedium was historically used in TCM for coronary heart disease and hypertension. Thrombosis-reducing activity has also been documented in animal models.
Icariin has been extensively studied in animal models of neurodegenerative disease and aging, demonstrating protection against cognitive decline through multiple mechanisms including amyloid-beta reduction, tau dephosphorylation, BDNF upregulation, and anti-neuroinflammation. It also delays aging-associated neurological changes in rodents. No human cognitive aging trials have been published.
Icariin has demonstrated antidepressant effects in multiple rodent models, including forced swim and chronic mild stress paradigms, by modulating monoamine neurotransmitter systems and reducing neuroinflammation. Animal studies show ICA increases BDNF, normalizes HPA axis activity, and reduces pro-inflammatory cytokines in brain tissue. No controlled human clinical trials for depression have been published.
Icariin from Barrenwort inhibits phosphodiesterase type 5 (PDE5) and upregulates endothelial and neuronal nitric oxide synthase (eNOS/nNOS) in penile tissue, mechanisms directly relevant to erectile function. Animal studies demonstrate dose-dependent improvements in intracavernous pressure and smooth muscle preservation in nerve-injured rats. Epimedium has been used in Chinese clinical preparations for erectile dysfunction, though large-scale controlled human trials remain limited.
Epimedium prenylflavonoids, including icariin, act as phytoestrogens by binding to estrogen receptors, exhibiting selective estrogen receptor modulator (SERM)-like properties. Human clinical studies confirm that ICA metabolites appear in serum of postmenopausal women after oral dosing and modulate estrogen-sensitive bone markers. Unlike classical estrogens, Epimedium prenylflavonoids did not activate androgen, glucocorticoid, or progesterone receptors in bioassays.
Icariin and its metabolite icariside II restore Sertoli cell function, improve sperm count and viability, and enhance testicular testosterone and estradiol in preclinical aging and chemotoxicity models. Animal data show ICA can activate ERK1/2 signaling to improve sperm quality. Epimedium has a traditional TCM indication for male reproductive deficiency and impotence.
Epimedium promotes estrogen production in ovarian granulosa cells and has been studied for premature ovarian failure (POF) in animal models, where it restores ovarian function via PI3K/AKT signaling. Preclinical evidence also suggests ICA reduces inflammatory signaling (NF-κB) involved in spontaneous abortion. Traditional TCM use includes female reproductive deficiency and menstrual irregularities.
Epimedium flavonoids—particularly icariin—have been reviewed as slow-aging agents with mechanisms spanning antioxidant activity, gene regulation (e.g., SIRT1), immune modulation, sex hormone regulation, and neuroprotection. The herb has been widely used clinically for aging-related diseases in China. Animal studies consistently show anti-aging effects across multiple organ systems.
Icariin exerts cardioprotective effects in animal models of heart failure and ischemia by suppressing NF-κB/caspase-3 signaling, elevating cGMP and Nrf2, and normalizing hemodynamics. Epimedium has demonstrated cardiovascular benefits including improved vascular reactivity and endothelial function in human subjects. TCM tradition includes its use for coronary heart disease.
Epimedium prenylflavonoids act as phytoestrogens binding estrogen receptors, providing a plausible mechanism for alleviating vasomotor symptoms like hot flashes in postmenopausal women. A publication in the Journal of Ethnopharmacology documented icariin's binding to estrogen receptors potentially alleviating menopausal discomfort. The 24-month human bone trial included menopausal women without reporting hyperplasia, suggesting a safe estrogenic profile.
Icariin exerts nephroprotective effects in multiple animal models of kidney disease including diabetic nephropathy, acute kidney injury, IgA nephropathy, chronic kidney disease, and lupus nephritis. Mechanisms include anti-fibrotic, antioxidant, anti-apoptotic, and anti-inflammatory activity. Traditional TCM use of Epimedium explicitly includes kidney-tonifying (renal tonic) functions.
Icariin attenuates memory and learning deficits in multiple rodent models of Alzheimer's disease and cognitive impairment, reducing amyloid-beta deposition, tau phosphorylation, and synaptic damage. The mechanism involves BDNF/TrkB/Akt pathway upregulation, improved brain insulin signaling, and anti-neuroinflammatory effects. All evidence is currently preclinical; human cognitive trials have not been conducted.
Icariin enhances endothelial nitric oxide synthase (eNOS) expression and NO production in human endothelial cells in both short- and long-term studies. It also produces NO-dependent vasorelaxation in coronary arterial rings via eNOS/cGMP pathway activation. This NO-upregulating activity underpins many of Barrenwort's cardiovascular and erectogenic properties.
Barrenwort (Epimedium, Yin Yang Huo) is a Traditional Chinese Medicine herb whose active compound icariin promotes osteoblast differentiation and inhibits osteoclastogenesis. Clinical trials of Epimedium-derived phytoestrogen flavonoids in postmenopausal women have shown reduced bone loss. It has been used in TCM for centuries for bone weakness and kidney deficiency.
Epimedium sagittatum has been studied for immunomodulatory and anti-inflammatory effects relevant to rheumatoid arthritis, including inhibition of TLR4/MD-2-mediated NF-κB signaling and reduction of TNF-α. Epimedium is listed in ethnopharmacological reviews as a treatment for rheumatic arthritis. Preclinical evidence supports immune and inflammatory target engagement; human RA-specific trials have not been published.
Icariin promotes testosterone synthesis by stimulating Leydig cells via ERα/Akt/CREB phosphorylation and by optimizing HPG axis signaling. Animal studies show ICA can restore testosterone levels in chemically-damaged or aged male reproductive systems. Evidence is primarily from animal models with no dedicated human RCTs confirming testosterone elevation.
Epimedium has a classical TCM indication for soreness and weakness of the back and knees, attributed to kidney yang deficiency. The Compendium of Materia Medica records its use to nourish essence, strengthen tendons and bones, and tonify the waist and knees. No clinical trials specifically targeting backache as a primary endpoint have been conducted.
Epimedium has a traditional TCM use for hypertension and has been studied in Chinese clinical preparations for high blood pressure. Icariin's vasodilatory and eNOS-upregulating properties provide biological plausibility. Controlled clinical trials specifically for blood pressure as a primary outcome have not been published.
Epimedium is classified in TCM as a tonic herb used for physical and mental fatigue, and is listed as an aphrodisiac and energy-enhancing agent. Its traditional use for fatigue is documented in ethnopharmacological literature. Icariin's effects on mitochondrial function, antioxidant defense, and testosterone support provide mechanistic plausibility.
Epimedium's common name 'horny goat weed' reflects its long-established TCM reputation as an aphrodisiac and male sexual tonic. It has been used for centuries to treat impotence, sexual dysfunction, and low libido. Preclinical studies support aphrodisiac effects via PDE5 inhibition and testosterone support, but controlled human libido trials have not been published.
Barrenwort (Epimedium species, also known as horny goat weed or Yin Yang Huo) has a 2,000-year history in TCM as a tonic for kidney deficiency and menopausal symptoms. Its primary compound icariin acts as a phytoestrogen and phosphodiesterase-5 inhibitor. It is listed in multiple authoritative menopause ingredient databases.
Epimedium has a classical TCM use for menopausal syndrome, including perimenopausal symptoms related to kidney deficiency and declining reproductive hormones. Its phytoestrogenic activity provides biological plausibility. The 2022 review confirms its broad clinical use in China for aging and hormone-related diseases including menopausal syndrome.
Body systems that Barrenwort may help support.
Go back